Processing & Storage Fees was Cryo Cell International’s largest product and service line in fiscal 2025, bringing in $31.38M of $31.57M (99%).
| Product and Service | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Processing & Storage Fees | $29.77M | $30.80M | $31.55M | $31.38M | ||||||||
| Umbilical Cord Blood & Cord Tissue Stem Cell Service | — | — | — | — | ||||||||
| Processing & Storage Royalties | — | — | — | — | ||||||||
| Licensee & Royalty Income | — | — | — | — | ||||||||
| Licensee & Royalty Income Recognition | — | — | — | — | ||||||||
| Public Banking | $461.63K | $481.15K | $366.67K | $129.51K | ||||||||
| Prepacyte Cb | — | — | — | — | ||||||||
| Public Banking Revenue | — | — | — | — | ||||||||
| Product | $104.00K | $66.46K | $67.88K | $54.10K | ||||||||
| Product Revenue | — | — | — | — | ||||||||
| Total | $30.34M | $31.34M | $31.99M | $31.57M |
Cryo Cell International brought in $31.57M from its three product and service lines in fiscal 2025, the year ended November 30, 2025. That was down 1.3% from $31.99M in fiscal 2024. Processing & Storage Fees was the largest at $31.38M (99.4%), ahead of Public Banking at $129.51K (0.4%) and Product at $54.10K (0.2%).
From fiscal 2022 to 2025, combined revenue from these lines grew from $30.34M to $31.57M, a compound annual growth rate of 1.3%. Processing & Storage Fees' share of the total rose from 98.1% to 99.4%.
Umbilical Cord Blood & Cord Tissue Stem Cell Service was Cryo Cell International’s largest segment in fiscal 2025, bringing in $31.38M of $31.57M (99%).
| Segment | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Umbilical Cord Blood & Cord Tissue Stem Cell Service | $29.77M | $30.80M | $31.55M | $31.38M | |||||
| Public Cord Blood Banking | $461.63K | $481.15K | $366.67K | $129.51K | |||||
| Prepacyte Cb | $104.00K | $66.46K | $67.88K | $54.10K | |||||
| Total | $30.34M | $31.34M | $31.99M | $31.57M |
Cryo Cell International brought in $31.57M from its three segments in fiscal 2025, the year ended November 30, 2025. That was down 1.3% from $31.99M in fiscal 2024. Umbilical Cord Blood & Cord Tissue Stem Cell Service was the largest at $31.38M (99.4%), ahead of Public Cord Blood Banking at $129.51K (0.4%) and Prepacyte Cb at $54.10K (0.2%).
From fiscal 2022 to 2025, combined revenue from these segments grew from $30.34M to $31.57M, a compound annual growth rate of 1.3%. Umbilical Cord Blood & Cord Tissue Stem Cell Service's share of the total rose from 98.1% to 99.4%.
Costa Rica was Cryo Cell International’s largest region in fiscal 2012, bringing in $25.00K of $45.00K (56%).
| Geography | FY 2012 |
|---|---|
| Costa Rica | $25.00K |
| Nicaragua | $20.00K |
| Total | $45.00K |
Cryo Cell International brought in $45.00K from its two regions in fiscal 2012, the year ended November 30, 2012. Costa Rica was the largest at $25.00K (55.6%), ahead of Nicaragua at $20.00K (44.4%).
Cryo Cell International (CCEL) reports its revenue by product and service, by segment and by geography. In fiscal 2025, Processing & Storage Fees was its largest product and service line, bringing in $31.38M (99.4% of the total), followed by Public Banking at $129.51K (0.4%).
Processing & Storage Fees was Cryo Cell International's largest product and service line in fiscal 2025, bringing in $31.38M, or 99.4% of the $31.57M total across its three product and service lines.
Umbilical Cord Blood & Cord Tissue Stem Cell Service was Cryo Cell International's largest segment in fiscal 2025, bringing in $31.38M, or 99.4% of the $31.57M total across its three segments.
Costa Rica was Cryo Cell International's largest region in fiscal 2012, bringing in $25.00K, or 55.6% of the $45.00K total across its two regions.
Every figure comes from Cryo Cell International's annual financial filings, as reported. Each line keeps the name Cryo Cell International gives it, and years follow its fiscal calendar.
Cryo Cell International's revenue by product and service goes back to fiscal 2014, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.